Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 4, 2004, Pages 1106-1112

  Patel, Ashish B ^a,b   Edelman, Martin J ^a   Kwok, Young ^a   Krasna, Mark J ^a   Suntharalingam, Mohan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Combined modality therapy; Esophagitis; Hyperfractionated radiotherapy; Non small cell lung cancer

Indexed keywords

CARCINOGENS; CELLS; CHEMOTHERAPY; DOSIMETRY; PARAMETER ESTIMATION; RADIOTHERAPY; REGRESSION ANALYSIS; SURGERY; TOXICITY;

BODY MASS INDEX; NON-SMALL-CELLS; PLASMA CONCENTRATION; TRIMODALITY PROTOCOLS;

PATIENT MONITORING;

DOCETAXEL; NAVELBINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSIMETRY; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; VINBLASTINE;

EID: 7444249045     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.04.051     Document Type: Article

References (25)

1. Dillman R.O., Seagren S.L., Propert K.L., et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 323:1990;940-994
2. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial of hyperfractionated radiation therapy with and without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol. 13:1995;452-458
3. Sause W., Kolesar P., Taylor S. IV, et al. Five-year results of phase III trial in regionally advanced unresectable non-small cell lung cancer Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 117:2000;358-364
4. Curran W.J., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable stage III NSCLC RTOG 9410. [Abstract] Proc Am Soc Clin Oncol. 22:2003;2499
5. Choy H., Akerly W., Safran H., et al. Multiinstitutional Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol. 16:1998;3316-3322
6. Byhardt R.W., Scott C., Sause W.T., et al. Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 42:1998;469-478
7. Maguire P.D., Sibley G.S., Zhou S.M., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 45:1999;97-103
8. Warner-Wasik M., Pequignot E., Leeper D., et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus A multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys. 48:2000;689-696
9. Singh A.K., Lockett M., Bradley J.D. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 55:2003;337-341
10. Taimur S., Edelman M.J., Suntharalingam M., et al. Intensified combined modality therapy for stage III non-small cell lung cancer Phase I/II trial of hyperfractionated radiotherapy with concurrent carboplatin/vinorelbine followed by individualized surgery and chemotherapy. [Abstract] Proc Am Soc Clin Oncol. 22:2003;2614
11. Greco F.A., Brereton H.D., Kent H., et al. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med. 85:1976;294-298
12. Umsawadasi T., Valdevieso M.V., Barkley T., et al. Esophageal complications from combined chemoradiotherapy (cyclophosphamide + adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 11:1984;511-519
13. Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 4:1986;14-22
14. Green M.R., Kramar A., Schilsky R., et al. Platinum-based combination chemotherapy in advanced non-small cell lung cancer A randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol. 18:1990;197-202
15. Choy H., Devore R.F., Hande K.R., et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center affiliate network study). Int J Radiat Oncol Biol Phys. 47:2000;931-937
16. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699
17. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy Possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555
18. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer A randomized study. J Clin Oncol. 14:1996;1065-1070
19. Vokes E.E., Herndon J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer Cancer and Leukemia Group B study 9431. J Clin Oncol. 20:2002;4191-4198
20. Langer CJ, Movsas B, Hudes R, et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center study 94-001. Semin Oncol 1997;24(4 Suppl 12):89-95
21. Huang E.Y., Wang C.J., Chen H.C., et al. Multivariate analysis of pulmonary fibrosis after electron beam irradiation for postmastectomy chest wall and regional lymphatics Evidence for non-dosimetric factors. Radiother Oncol. 57:2000;91-96
22. Nelson K.A., Walsh D., Sheehan F.A. The cancer anorexia-cachexia syndrome. J Clin Oncol. 15:1994;213-225
23. Nathanson L., Puccio M. The cancer cachexia syndrome. Semin Oncol. 274:1997;277-287
24. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:1991;109-122
25. Hirota S., Tsujino K., Endo M., et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys. 51:2001;291-295